Clinical Trial Update: A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 multicenter, double-blind, placebo-controlled safety and tolerability study of BMS-708163 in prodromal Alzheimer's disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• BMS-708163 (semagacestat) (semagacestat)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED